Choose a language and wait for the translated text.
The Chinese biotech will use its proprietary AI-driven drug-delivery platform to develop next-generation technologies aimed at improving how LNP-based drugs reach target tissues.
HK-listed Metis TechBio, Eli Lilly strike drug-delivery deal worth up to $1.1 billion | PharmaVoice
